Radiation “spot treatments” for a few metastatic or worsening spots
Part of Cancer clinical trials.
This trial compares giving stereotactic ablative radiotherapy as one larger treatment plan versus several smaller plans for people who have only a few cancer spots (or a few spots that are worsening). It may help control metastatic disease while aiming to protect surrounding healthy organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can legally consent to join the study.
- You currently have 1 to 5 cancer spots, or only a few spots that are progressing.
- You are expected to live more than 6 months.
- You must be well enough for treatment (ECOG performance status 0–2) and have had a recent checkup within 6 weeks.
- You need recent scans within set time windows (CT/PET-CT for chest/abdomen/pelvis, and a bone scan unless you already had PET-CT).
- Your main cancer must be “controlled,” meaning it has been treated at the original site and has not grown there for at least 3 months (or there is no visible primary tumor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of radiation for people whose cancer has spread to a few new spots while on or after treatment. It tests whether a precise, high-dose radiation approach (stereotactic) works better than the usual palliative radiation for controlling these growing spots.
This trial compares two types of highly focused radiation (ablative radiosurgery versus stereotactic radiation in 5 sessions) for people with a small number of metastases in the bone. It aims to find which approach controls these spots with fewer side effects while keeping the treatment “radical,” meaning trying to wipe out the targeted lesions.
This trial tests a precise, high-dose radiation treatment (SABR) for people whose cancer has spread to a few spots (up to 5) and is not growing in the brain or been previously treated with radiation in those same spots.
This trial tests whether high-precision radiation (SBRT) can improve outcomes for people with up to 5 small, stable metastases from certain cancers, compared to usual palliative care. It is for those whose disease is not growing after current chemotherapy.
This trial tests whether a precise form of high-dose radiation can control up to 1–5 breast cancer metastases (spread) in a few body areas. It may help by focusing treatment only on visible spots while limiting radiation to the rest of the body.
This study is for people with solid tumors that have spread to a few spots (5 or fewer) in the body. It tests whether using a focused treatment like radiation or ablation on those spots can help control the cancer long-term.
Hear when a new Oligometastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.